Bristol-Myers gets shareholder approval for $74B Celgene deal
Bristol-Myers Squibb Co. on Friday won a shareholder vote to approve its takeover of Celgene Corp., paving the way to close the largest pharmaceutical merger in history and create a cancer-drug giant.